Add like
Add dislike
Add to saved papers

MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.

Emerging reports suggest microRNAs (miRNAs) play a vital role in the progression of malignant tumors. MiR-30a is downregulated in a variety of cancers and acts as a tumor suppressing gene. However, the molecular mechanisms of miRNA-30a in hepatocellular carcinoma (HCC) are still unclear. Hereby, in this study, we detected that miR-30a expression was significantly down-regulated in both HCC tissues compared with adjacent non-cancerous liver tissues, and we also observed that miR-30a expression was lower in HCC cell lines than that of normal controls. By overexpression of miRNA-30a, we evaluated cell growth with CCK-8 assay and cell apoptosis by flow cytometry. The function of miR-30a on cellular migration in HCC cells was assessed. The potential target genes of miR-30a were analyzed with luciferase activity assay. Our data displayed that miR-30a mimic markedly inhibited HCC cell growth, induced cell apoptosis, and upregulated the expression of apoptotic proteins in HepG2 and MHCC976L cells. We also found that upregulation of miR-30a significantly inhibited HCC cells migration and invasion. Bioinformatics analysis revealed K-Ras was a regulative target gene of miR-30a, and further dual luciferase reporter assay showed that miR-30a directly binds to the 3'-untranslated region (3'-UTR) of K-Ras mRNA. Furthermore, we found that in HepG2 and MHCC97L cancer cells, miR-30a overexpression completely blocked the K-Ras/c-Raf/MEK/ERK pathway activation. Overall, these findings demonstrated that miR-30a might play a certain role in the cell growth, apoptosis and metastasis of HCC cells, partially via regulating K-Ras/c-Raf/MEK/ERK signaling pathway, potentially, it is therefore a candidate targeting biomarker for HCC therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app